MBS303

Phase 2Small molecule

BBeijing Mabworks Biotech Co., Ltd.

MBS303 is one of 3 small molecule programs targeting B-cell NHL. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

B-Cell NHLRecruiting

B-Cell NHLPhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in B-Cell NHL

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 2

2 2

Calquence

AstraZeneca

Phase 2

1 3

MBS303

BBeijing Mabworks Biotech Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

B-Cell NHL

NCT05806099

Clinical

Trials by Indication[1]

B-cell NHL1 trial

A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL

Recruiting·BBeijing Mabworks Biotech Co., Ltd.·Phase 1/2·NCT05806099·132 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MBS303. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MBS303 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MBS303. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Mabworks Biotech Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBeijing Mabworks Biotech Co., Ltd.

MBS303

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

B-cell NHL1 trial

References

Drug Info

Quick Facts

Related News